Breaking News
Get 45% Off 0
Is it finally time to sell Nvidia ahead of earnings?
Read More

PetMed (PET) Focuses On Advertising To Boost New Order Sales

By Zacks Investment ResearchStock MarketsFeb 26, 2018 09:48PM ET
www.investing.com/analysis/petmed-pet-focuses-on-advertising-to-boost-new-order-sales-200294707
PetMed (PET) Focuses On Advertising To Boost New Order Sales
By Zacks Investment Research   |  Feb 26, 2018 09:48PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
BDX
-0.50%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
RVTY
+0.18%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
FMC
+0.79%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PETS
+0.11%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BIO
-1.57%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

On Feb 26, we issued an updated research report on PetMed Express, Inc. (NASDAQ:PETS) . The stock carries a Zacks Rank #1 (Strong Buy). The company is striving to implement several strategies to revitalize its top line. These include increased focus on advertising efficiency to boost new order sales and shifting sales to higher margin items, while also expanding the product line.

After several quarters of a drag in new order sales, we are impressed with PetMed’s improved performance last fiscal. The current year has demonstrated bullish momentum so far. PetMed is also working on improving the effectiveness of its campaigns. It has been quite successful in driving its sales via the Internet.

PetMed offers a wide range of products for dogs, cats and horses. We believe with the improvement in economic conditions, PetMed’s wide range of products will help drive growth in the coming quarters.

However, with an aim to increase the recognition of its brand names, PetMed markets its products through national advertising campaigns. Under this procedure, the company has been incurring huge expenses related to advertising campaigns in recent times. Hence, escalating advertising expenses exert pressure on the bottom line. Also, a tough competitive landscape is a major concern.

Stock Performance & Estimate Revision

Over the last year, PetMed has outperformed its industry. The company has gained 123.9% compared with 65.9% of the industry.

Also, the estimate revision trend for the current year is favorable with one estimate moving north over the last two months, compared with no movement in the opposite direction. Earnings estimates moved up 6.7% to $1.76.

Other Key Picks

Other top-ranked stocks in the broader medical sector are PerkinElmer (NYSE:PKI) , Bio-Rad Laboratories (NYSE:BIO) and Becton, Dickinson and Company (NYSE:BDX) .

Bio-Rad Laboratories has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 25%.

PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.

Becton, Dickinson and Company is a Zacks #2 Ranked player. The company has a long-term expected earnings growth rate of 13.3%.

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp (NYSE:FMC). and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >>



PetMed Express, Inc. (PETS): Free Stock Analysis Report

PerkinElmer, Inc. (PKI): Free Stock Analysis Report

Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Original post

Zacks Investment Research

PetMed (PET) Focuses On Advertising To Boost New Order Sales
 

Related Articles

PetMed (PET) Focuses On Advertising To Boost New Order Sales

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email